|
| | Mubritinib Basic information |
| Product Name: | Mubritinib | | Synonyms: | MUBRITINIB;1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole;TAK 165;Mubritinib(TAK 165);CS-522;TAK165;TAK-165;(E)-1-(4-(4-((2-(4-(trifluoromethyl)styryl)oxazol-4-yl)methoxy)phenyl)butyl)-1H-1,2,3-triazole;1-(4-(4-((2-((1E)-2-(4-(Trifluoromethyl)phenyl)ethenyl)-4-oxazolyl)methoxy)phenyl)butyl)-1H-1,2,3-triazole Mubritinib (TAK 165) | | CAS: | 366017-09-6 | | MF: | C25H23F3N4O2 | | MW: | 468.47 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 366017-09-6.mol |  |
| | Mubritinib Chemical Properties |
| Melting point | 158.0 to 162.0 °C | | Boiling point | 620.9±65.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | DMSO : 50 mg/mL (106.73 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | | pka | 1.45±0.10(Predicted) | | form | powder to crystal | | color | White to Gray to Brown |
| | Mubritinib Usage And Synthesis |
| Uses | Treatment of cancer. | | Uses | Mubritinib is used in selective targeting of CTNNB1-, KRAS-or MYC-driven human cancer cell growth by combinations of existing drugs | | Biological Activity | Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC 50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC 50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo . | | storage | Store at +4°C |
| | Mubritinib Preparation Products And Raw materials |
|
